TY - JOUR
T1 - Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma
AU - Kajiyama, Hiroaki
AU - Suzuki, Shiro
AU - Utsumi, Fumi
AU - Yoshikawa, Nobuhisa
AU - Nishino, Kimihiro
AU - Ikeda, Yoshiki
AU - Niimi, Kaoru
AU - Yamamoto, Eiko
AU - Kawai, Michiyasu
AU - Shibata, Kiyosumi
AU - Nagasaka, Tetsuro
AU - Kikkawa, Fumitaka
N1 - Publisher Copyright:
© Japan Society of Clinical Oncology 2019.
PY - 2019/8
Y1 - 2019/8
N2 - Background Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage. Materials and methods The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III–IV PmOC, were retrospectively analyzed. The prognostic significances of clinicopathologic factors were evaluated employing both uni-and multivariable analyses. Pathological slides were evaluated based on centralized pathological review. Results The median age of patients with PmOC and MmOC was 55 (18–81) and 51 years (30–82), respectively. With follow-up of a total of 167 patients, 145 patients (86.8%) developed recurrence. In addition, 122 patients (73.0%) died of the disease. Regardless of the residual tumor status, patients with PmOC did not a show a significantly poorer OS than those with MmOC. Furthermore, in a Cox multivariable hazard model, after adjustment for various clinicopathologic confounders, a gastric cancer (GC)-originated tumor and larger residual tumor were significant predictors of poorer OS [GC (vs. PmOC): HR (95% CI) 2.205 (1.303–3.654), P = 0.0036]. Conclusion The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy.
AB - Background Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage. Materials and methods The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III–IV PmOC, were retrospectively analyzed. The prognostic significances of clinicopathologic factors were evaluated employing both uni-and multivariable analyses. Pathological slides were evaluated based on centralized pathological review. Results The median age of patients with PmOC and MmOC was 55 (18–81) and 51 years (30–82), respectively. With follow-up of a total of 167 patients, 145 patients (86.8%) developed recurrence. In addition, 122 patients (73.0%) died of the disease. Regardless of the residual tumor status, patients with PmOC did not a show a significantly poorer OS than those with MmOC. Furthermore, in a Cox multivariable hazard model, after adjustment for various clinicopathologic confounders, a gastric cancer (GC)-originated tumor and larger residual tumor were significant predictors of poorer OS [GC (vs. PmOC): HR (95% CI) 2.205 (1.303–3.654), P = 0.0036]. Conclusion The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy.
KW - Gastric carcinoma
KW - Metastatic ovarian carcinoma
KW - Mucinous epithelial ovarian carcinoma
KW - Overall survival
KW - Residual tumor
UR - http://www.scopus.com/inward/record.url?scp=85064260332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064260332&partnerID=8YFLogxK
U2 - 10.1007/s10147-019-01438-6
DO - 10.1007/s10147-019-01438-6
M3 - Article
C2 - 30941534
AN - SCOPUS:85064260332
SN - 1341-9625
VL - 24
SP - 950
EP - 956
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 8
ER -